Budget Impact

Although not yet included in NICE Melanoma NG14 Guidelines, there is potential for AMBLor® to be used as a rule-out test, allowing low risk people to be directed on different pathways, as appropriate. By reducing the overall number of follow-up visits required for those at identified as low risk, use of AMBLor® could: [1,2]

  • Reduce costs by between £2.09 and £244.76 (average £175.18) per person by cutting the number of follow-up appointments by up to 12 visits*
  • Enable clinicians to focus on at-risk people
  • Help alleviate anxiety and the burden of follow-up for people identified as low risk
  • Reduce costs by between £2.09 and £244.76 (average £175.18) per person by cutting the number of follow-up appointments by up to 12 visits*
  • Enable clinicians to focus on at-risk people
  • Help alleviate anxiety and the burden of follow-up for people identified as low risk

Potential savings for 100 people with confirmed melanoma screened with AMBLor® and a reduced follow-up pathway implemented [1,2]

Stage
IA
IB
IIA
IIB
% diagnosed by stage
43.9%
25.3%
12.5%
7.7%
Number of people by stage
44
25
13
8
Saving per person using AMBLor®
£2.09
£225.58
£244.76
£228.29
Total
Saving per 100 representative people using AMBLor®
£91.96
£5,639.50
£3,181.88
£1,826.32
£10,739.66

Standard of care costs would remain the same for people identified as at risk, with the existing recommended number of follow-up visits. [1,2]

In addition, use of AMBLor® could identify genuinely low-risk people to help guide appropriate use of sentinel lymph node biopsy (SLNB). The savings include a reduction in unnecessary SLNBs for low risk people and the attendant complication rate of 13.8% (in the UK). [1,2]

* Based on reducing NICE Melanoma pathway (NG14) recommendations for stage IB to IIC follow-up, 4 x per year for 3 years, 2 x per year for 2 years (=16 visits in total) to 4 visits over 4 years and stage IA follow-up, 2-4 per year for 1 year (=max 4 visits in total) to 1 visit at the end of year 1.

References

  1. AMLo Biosciences. Data on File: Budget Impact Model.
  2. NICE guideline [NG14]. Melanoma: Assessment and Management. Published: 29 July 2015.

Job code: 2021/AMBLor/UK/0021e
Date of preparation: February 2022

AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534

Trading address (Visitors and Deliveries): Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX   ///wider.admire.guard

Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom

VAT # 285288950

Sign up for our newsletter